Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) confirmed that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments Trader Talk Trading Halts

Regeneron (REGN) PRALUEN Panel Commentary Could Result in Narrower-Than-Expected Labeling, BMO Capital SaysJune 10, 2015 7:48 AM RBC Capital Comments on Regeneron (REGN) Following 'Unexpectedly Cautious' AdcomJune 10, 2015 7:09 AM Regeneron (REGN) Resumes Trading Up 1%June 9, 2015 6:50 PM Regeneron (REGN) to Resume Trading at 6:50PM ETJune 9, 2015 6:36 PM FDA Advisory Committee Recommends Approval of Regeneron and Sanofi's Praluent® (alirocumab) Injection for Patients with HypercholesterolemiaJune 9, 2015 6:30 PM After-Hours Stock Movers 06/09: (REGN) (CTIC) (SIGM) HIGHER; (SALT) (RXDX) (HRTX) LOWER (more...)June 9, 2015 6:05 PM Esperion (ESPR), Amgen (AMGN) Shares Weaken Post-Market After Praluent Gets FDA BackingJune 9, 2015 5:39 PM Regeneron (REGN) and Sanofi's (SNY) Praluent Wins FDA Panel Backing - BloombergJune 9, 2015 4:52 PM Trading in Regeneron Common Stock HaltedJune 9, 2015 7:05 AM Regeneron (REGN) Halted Ahead of FDA Panel Review of PraluentJune 9, 2015 6:56 AM